We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Aspira Womens Health Inc is transforming women's health with the discovery, development, and commercialization of testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1 plus combines its FDA-c... Aspira Womens Health Inc is transforming women's health with the discovery, development, and commercialization of testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1 plus combines its FDA-cleared products OVA1 and OVERA to detect the risk of ovarian malignancy in women with adnexal masses. Aspira GenetiX testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. Its focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment. Show more
AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development...
2023 OvaSuite revenue of $9.2 million, an increase of 15% year-over-year 2023 OvaSuite volume of 23,990 units, an increase of 12% year-over-year Cash utilization declined in both the fourth...
AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development...
AUSTIN, Texas, March 21, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development...
Dr. Milligan brings a wealth of experience across critical business functions and deep relationships with leaders throughout the healthcare and pharmaceutical sectors Aspira also announces Dr...
AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development...
AUSTIN, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.24 | -6.81818181818 | 3.52 | 3.57 | 3.2 | 6503 | 3.46473906 | CS |
4 | -0.22 | -6.28571428571 | 3.5 | 3.675 | 2.51 | 25014 | 3.03484898 | CS |
12 | -2.08 | -38.8059701493 | 5.36 | 5.45 | 2.51 | 23721 | 3.74890932 | CS |
26 | -2.08 | -38.8059701493 | 5.36 | 5.65 | 2.49 | 36617 | 3.85050936 | CS |
52 | -2.045 | -38.4037558685 | 5.325 | 6.75 | 2.3087 | 66651 | 4.13875951 | CS |
156 | -87.47 | -96.3856749311 | 90.75 | 95.85 | 2.3087 | 430032 | 25.8362664 | CS |
260 | -58.82 | -94.7181964573 | 62.1 | 158.1 | 2.3087 | 505758 | 43.9898999 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions